AMRX
Amneal Pharmaceuticals, Inc. NASDAQ Listed May 7, 2018$13.73
Mkt Cap $4.4B
52w Low $7.02
79.9% of range
52w High $15.42
50d MA $12.81
200d MA $11.66
P/E (TTM)
55.8x
EV/EBITDA
10.6x
P/B
675.3x
Debt/Equity
-38.6x
ROE
-101.8%
P/FCF
14.6x
RSI (14)
—
ATR (14)
—
Beta
1.32
50d MA
$12.81
200d MA
$11.66
Avg Volume
2.0M
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
400 Crossing Boulevard · Bridgewater, NJ 08807 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | AMC | 0.17 | 0.27 | +58.8% | 13.02 | +1.9% | -1.5% | -2.3% | +0.4% | +1.4% | +0.5% | — |
| Feb 27, 2026 | AMC | 0.18 | 0.21 | +16.7% | 14.49 | -1.8% | -4.7% | -3.6% | -0.1% | -0.3% | -0.2% | — |
| Oct 30, 2025 | AMC | 0.13 | 0.17 | +30.8% | 10.43 | +1.8% | -4.1% | +12.0% | +1.3% | +3.0% | -0.3% | — |
| Aug 5, 2025 | AMC | 0.18 | 0.25 | +38.9% | 7.96 | +4.1% | +2.1% | +1.0% | +4.0% | +3.5% | +2.0% | — |
| May 2, 2025 | AMC | 0.15 | 0.21 | +40.0% | 7.74 | +0.6% | +3.0% | -9.9% | +0.6% | +3.3% | -0.7% | — |
| Feb 28, 2025 | AMC | 0.15 | 0.12 | -20.0% | 8.38 | -5.0% | +3.5% | +2.0% | +1.5% | -2.3% | +1.6% | — |
| Nov 8, 2024 | AMC | 0.13 | 0.16 | +23.1% | 8.61 | -5.3% | +1.4% | +6.0% | -2.4% | -0.3% | -5.9% | — |
| Aug 9, 2024 | AMC | 0.14 | 0.16 | +14.3% | 7.77 | -1.3% | -1.5% | +2.7% | -0.6% | +1.3% | +1.6% | — |
| May 3, 2024 | AMC | 0.09 | 0.14 | +55.6% | 6.21 | +0.6% | +8.9% | -3.7% | +1.2% | -1.8% | +2.9% | — |
| Mar 1, 2024 | AMC | 0.07 | 0.14 | +100.0% | 5.52 | +10.9% | -0.9% | -2.4% | -0.6% | +0.0% | +1.5% | — |
| Nov 7, 2023 | AMC | 0.12 | 0.19 | +58.3% | 4.21 | -0.7% | +2.4% | -3.7% | +1.7% | +1.4% | +6.8% | — |
| Aug 4, 2023 | AMC | 0.10 | 0.19 | +90.0% | 3.36 | +7.1% | +22.3% | +9.0% | -5.6% | +0.0% | -6.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2 | Truist | Maintains | Buy → Buy | — | $13.81 | $13.87 | +0.4% | -0.3% | -3.3% | -0.1% | -0.3% | -0.2% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.00 | $10.18 | +1.8% | +8.2% | +3.5% | +1.3% | +3.0% | -0.3% |
| Sep 16 | JP Morgan | Maintains | Overweight → Overweight | — | $9.79 | $9.83 | +0.4% | -0.5% | -1.3% | +2.1% | +0.0% | +1.9% |
| Mar 3 | Barclays | Maintains | Overweight → Overweight | — | $8.67 | $8.69 | +0.2% | +1.0% | +0.9% | +1.5% | -2.3% | +1.6% |
| Feb 24 | JP Morgan | Upgrade | Neutral → Overweight | — | $7.83 | $8.49 | +8.4% | +6.0% | +2.4% | -0.8% | -0.6% | +3.5% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.73 | $8.79 | +0.7% | +5.4% | +0.5% | -2.4% | -0.3% | -5.9% |
| Oct 2 | Truist | Maintains | Buy → Buy | — | $8.70 | $8.76 | +0.7% | -1.3% | -0.5% | +1.2% | -2.2% | +2.4% |
| Sep 6 | JP Morgan | Upgrade | Underweight → Neutral | — | $8.45 | $8.56 | +1.3% | -0.7% | +0.8% | -0.9% | -0.2% | +1.3% |
| Aug 13 | Barclays | Maintains | Overweight → Overweight | — | $7.54 | $7.47 | -0.9% | +4.2% | -0.6% | +1.3% | +1.6% | +1.4% |
| Aug 12 | Truist | Maintains | Buy → Buy | — | $7.65 | $7.77 | +1.6% | -1.4% | +4.2% | -0.6% | +1.3% | +1.6% |
| May 6 | Truist | Maintains | Buy → Buy | — | $6.76 | $6.82 | +0.9% | -1.6% | -2.1% | +1.2% | -1.8% | +2.9% |
| May 6 | Goldman Sachs | Maintains | Buy → Buy | — | $6.76 | $6.82 | +0.9% | -1.6% | -2.1% | +1.2% | -1.8% | +2.9% |
| Mar 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.08 | $6.32 | +3.9% | +3.5% | -3.5% | -2.6% | -1.0% | +4.6% |
| Mar 4 | Goldman Sachs | Maintains | Buy → Buy | — | $5.47 | $5.43 | -0.7% | -1.3% | -1.1% | -0.6% | +0.0% | +1.5% |
| Jan 29 | Barclays | Maintains | Overweight → Overweight | — | $5.49 | $5.64 | +2.7% | +4.9% | -4.3% | -2.9% | +3.0% | +0.2% |
| Nov 8 | Truist | Maintains | Buy → Buy | — | $4.31 | $4.38 | +1.6% | -5.8% | +2.2% | +1.7% | +1.4% | +6.8% |
| Sep 6 | Truist | Maintains | Buy → Buy | — | $3.82 | $3.94 | +3.1% | -3.1% | +0.0% | +1.9% | +1.9% | +4.2% |
| Aug 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.11 | $4.27 | +3.9% | +11.7% | -2.4% | -5.6% | +0.0% | -6.1% |
| Aug 7 | Truist | Maintains | Buy → Buy | — | $4.11 | $4.27 | +3.9% | +11.7% | -2.4% | -5.6% | +0.0% | -6.1% |
| Aug 7 | Barclays | Maintains | Overweight → Overweight | — | $4.11 | $4.27 | +3.9% | +11.7% | -2.4% | -5.6% | +0.0% | -6.1% |
| May 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.92 | $2.00 | +4.2% | +5.2% | -7.9% | -4.3% | +5.6% | +2.1% |
| Mar 29 | Truist | Maintains | Buy → Buy | — | $1.27 | $1.29 | +1.6% | +3.1% | +3.8% | +2.2% | +4.3% | -6.2% |
| Mar 10 | Barclays | Maintains | Overweight → Overweight | — | $1.67 | $1.64 | -1.8% | -8.4% | -3.9% | -2.7% | -4.9% | -0.7% |
| Mar 3 | BMO Capital | Maintains | Market Perform → Market Perform | — | $1.99 | $1.98 | -0.5% | -3.5% | -5.2% | -3.3% | -4.5% | -0.6% |
| Mar 3 | Goldman Sachs | Maintains | Buy → Buy | — | $1.99 | $1.98 | -0.5% | -3.5% | -5.2% | -3.3% | -4.5% | -0.6% |
| Aug 8 | Goldman Sachs | Maintains | Buy → Buy | — | $3.18 | $3.17 | -0.3% | -1.6% | -1.3% | +1.6% | -7.0% | +8.2% |
| May 12 | Goldman Sachs | Maintains | Buy → Buy | — | $3.26 | $3.26 | +0.0% | +4.3% | +1.5% | -0.6% | +7.9% | -5.9% |
| Mar 8 | Goldman Sachs | Upgrade | Sell → Buy | — | $4.95 | $5.15 | +4.0% | +13.1% | +6.8% | -1.2% | +3.9% | -2.0% |
| Dec 14 | Guggenheim | Upgrade | Neutral → Buy | — | $4.08 | $4.37 | +7.1% | +7.6% | +5.5% | -1.1% | -0.9% | -3.1% |
| Nov 9 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $4.13 | $4.27 | +3.4% | +1.5% | +0.0% | -0.7% | -0.7% | +0.2% |
| Oct 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.53 | $4.60 | +1.5% | +4.9% | +1.3% | -0.8% | +2.5% | +3.1% |
| Jul 27 | Goldman Sachs | Maintains | Sell → Sell | — | $4.29 | $4.25 | -0.9% | -4.2% | +1.9% | +8.6% | -4.2% | -0.7% |
| May 13 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $4.27 | $4.31 | +0.9% | +2.1% | -6.0% | +0.5% | +6.3% | +3.4% |
| May 12 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $4.56 | $4.65 | +2.0% | -6.4% | +2.1% | -6.0% | +0.5% | +6.3% |
| May 12 | Guggenheim | Upgrade | Sell → Neutral | — | $4.56 | $4.65 | +2.0% | -6.4% | +2.1% | -6.0% | +0.5% | +6.3% |
| Apr 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.03 | $3.10 | +2.3% | +0.7% | -5.9% | +9.4% | -7.3% | +6.5% |
| Feb 27 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $3.85 | $3.90 | +1.3% | -1.6% | +1.6% | +3.4% | -4.0% | +7.1% |
| Jan 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $4.82 | $4.98 | +3.3% | -1.0% | -1.0% | +0.2% | -1.1% | -3.4% |
| Dec 12 | Raymond James | Downgrade | Outperform → Market Perform | — | $3.48 | $4.69 | +34.8% | +44.8% | -5.6% | +16.8% | -7.6% | -4.1% |
| Nov 12 | JP Morgan | Downgrade | Neutral → Underweight | — | $2.65 | $2.58 | -2.6% | +1.9% | +1.9% | -1.5% | +1.5% | +2.9% |
| Nov 11 | BMO Capital | Maintains | Market Perform → Market Perform | — | $2.73 | $2.70 | -1.1% | -2.9% | +1.9% | +1.9% | -1.5% | +1.5% |
| Nov 7 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $2.76 | $2.71 | -1.8% | -4.0% | +3.0% | -2.9% | +1.9% | +1.9% |
| Nov 7 | Raymond James | Maintains | Outperform → Outperform | — | $2.76 | $2.71 | -1.8% | -4.0% | +3.0% | -2.9% | +1.9% | +1.9% |
| Sep 12 | Guggenheim | Maintains | Sell → Sell | — | $3.46 | $3.25 | -6.1% | +0.9% | +0.0% | -4.3% | -5.1% | +2.8% |
| Aug 6 | BMO Capital | Maintains | Market Perform → Market Perform | — | $3.02 | $3.06 | +1.3% | -1.0% | -2.7% | +2.7% | -2.7% | -2.4% |
| Jul 22 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $3.40 | $3.60 | +5.9% | +1.2% | +6.7% | -0.3% | -3.6% | +3.4% |
| Jul 11 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $4.36 | $4.37 | +0.2% | -7.1% | -8.6% | -5.1% | -6.8% | +4.0% |
| Jul 11 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $4.36 | $4.37 | +0.2% | -7.1% | -8.6% | -5.1% | -6.8% | +4.0% |
| Jul 10 | Raymond James | Downgrade | Strong Buy → Outperform | — | $6.81 | $5.05 | -25.8% | -36.0% | -7.1% | -8.6% | -5.1% | -6.8% |
| Jul 8 | Piper Jaffray | Upgrade | Neutral → Overweight | — | $6.66 | $7.28 | +9.3% | +1.2% | +1.0% | -36.0% | -7.1% | -8.6% |
No insider trades available.
8-K
Amneal Pharmaceuticals, Inc. -- 8-K Filing
Amneal Pharmaceuticals acquired Kashiv product candidates with potential royalty payments to sellers of up to 25% of profits exceeding specified thresholds over twelve years.
Apr 22
8-K · 7.01
! Medium
Amneal Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Amneal Pharmaceuticals will host an earnings call today at 8:30 a.m. ET to discuss financial results, accessible via webcast on its investor relations website.
Feb 27
8-K · 1.01
!! High
Amneal Pharmaceuticals, Inc. -- 8-K 1.01: Material Agreement
Amneal Pharmaceuticals repriced its term loan credit agreement, likely reducing borrowing costs and improving financial flexibility for the pharmaceutical company.
Feb 3
Data updated apr 24, 2026 5:56pm
· Source: massive.com